Pea F.; Bertolissi M.; Di Silvestre A.; Poz D.; Giordano F.; Furlanut M., TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients, «INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS», 2002, 20, pp. 326 - 332 [articolo]
Scotton P.G.; Pea F.; Giobbia M.; Baraldo M.; Vaglia A.; Furlanut M., Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis, «CLINICAL INFECTIOUS DISEASES», 2001, 33, pp. e109 - e111 [articolo]
Baraldo M.; Pea F.; Poz D.; Albanese M.C.; Livi U.; Furlanut M., Cyclosporine dose fractioning might affect renal function in stable heart transplanted patients, «TRANSPLANTATION PROCEEDINGS», 2001, 33, pp. 3151 - 3153 [articolo]
Baraldo M.; Pea F.; Poz D.; Furlanut M., Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients, «PHARMACOLOGICAL RESEARCH», 2001, 43, pp. 547 - 551 [articolo]
Brusaferro S.; Rinaldi O.; Pea F.; Faruzzo A.; Barbone F., Protocol implementation in hospital infection control practice: An Italian experience of preoperative antibiotic prophylaxis, «THE JOURNAL OF HOSPITAL INFECTION», 2001, 47, pp. 288 - 293 [articolo]
Pea F.; Brollo L.; Lugano M.; Pos L.D.; Furlanut M., Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration, «THERAPEUTIC DRUG MONITORING», 2001, 23, pp. 587 - 588 [replica/breve intervento]
Pea F.; Milaneschi R.; Baraldo M.; Lugatti E.; Talmassons G.; Furlanut M., Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): Comparative pharmacokinetics and the role of therapeutic drug monitoring, «THERAPEUTIC DRUG MONITORING», 2000, 22, pp. 386 - 391 [articolo]
PEA, Federico; PORRECA2, L2; BARALDO, Massimo; FURLANUT, Mario, High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2000, 45, pp. 329 - 335 [articolo]
Pea F.; Russo D.; Michieli M.; Baraldo M.; Ermacora A.; Damiani D.; Baccarani M.; Furlanut M., Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia, «CANCER CHEMOTHERAPY AND PHARMACOLOGY», 2000, 46, pp. 279 - 286 [articolo]
Ermacora, A; Michieli, M; Pea, F; Visani, G; Bucalossi, A; Russo, D, Liposome encapsulated daunorubicin (daunoxome) for acute leukemia, «HAEMATOLOGICA», 2000, 85, pp. 324 - 325 [replica/breve intervento]
PEA, Federico; POZ, Donatella; BARALDO, Massimo; FURLANUT, Mario, Optimisation of vancomycin regimen in neutropenic haematological patients with normal renal function. Multiple daily doses may be preferable, «CLINICAL DRUG INVESTIGATION», 2000, 19, pp. 213 - 218 [replica/breve intervento]
Pea F.; Furlanut M.; Bianchi L., Systemic vancomycin overexposure in a patient with spinal cord injury who had staphylococcal sepsis and Clostridium difficile colitis, «THERAPEUTIC DRUG MONITORING», 2000, 22, pp. 233 - 234 [replica/breve intervento]
Baraldo M.; Ferraccioli G.; Pea F.; Gremese E.; Furlanut M., Cyclosporine a pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy, «PHARMACOLOGICAL RESEARCH», 1999, 40, pp. 483 - 486 [articolo]
Pea F.; Milaneschi R.; Baraldo M.; Talmassons G.; Furlanut M., Isoniazid and its hydrazine metabolite in patients with tuberculosis, «CLINICAL DRUG INVESTIGATION», 1999, 17, pp. 145 - 154 [articolo]
Michieli M.; Damiani D.; Ermacora A.; Masolini P.; Michelutti A.; Michelutti T.; Russo D.; Pea F.; Baccarani M., Liposome-encapsulated daunorubicin for PGP-related multidrug resistance, «BRITISH JOURNAL OF HAEMATOLOGY», 1999, 106, pp. 92 - 99 [articolo]
